Search the Newsreel

Goldman Sachs (GS) Launches Retail Private Markets Fund As CEO Backs Crypto Bill

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Goldman Sachs Group (NYSE:GS) and T. Rowe Price have partnered to launch a private markets interval fund aimed at retail investors. The new fund is …

AI-Fueled Demand Signals a Bigger Opportunity for Bloom Energy (BE) Investors

According to Goldman Sachs projections, U.S. data center power demand could more than double from 31 gigawatts in 2025 to 66 gigawatts by 2027. BloombergNEF also estimates that data centers could account for 20% of U.S. electricity consumption by 2035. That would mark almost …

Umicore - Transparency notification by The Goldman Sachs Group, Inc

Umicore Transparency notification by The Goldman Sachs Group, Inc In accordance with article 14, § 1 of the law of 2 May 2007 on the disclosure of major holdings, Umicore was recently notified by The Goldman Sachs Group, Inc that it has crossed the …

Is GAMDX a Strong Bond Fund Right Now?

Any investors hoping to find a International Bond - Emerging fund might consider looking past Goldman Sachs Local Emerging Markets Debt A (GAMDX). GAMDX possesses a Zacks Mutual Fund Rank of 5 (Strong Sell), which is based on various forecasting factors like size, cost, …

Gossamer Bio Inc (GOSS) Institutional Confidence

Gossamer Bio Inc (GOSS) has an institutional shareholding score of 7.00, placing it 80th out of 385 in its industry. The latest institutional shareholding proportion is 73.39%, representing a quarterly decrease of 6.63%. James Simons is identified as the largest institutional shareholder, holding 0.52% …

US Says Ex-Goldman Banker Berko Paid a ‘Holy Rain’ of Bribes

(Bloomberg) -- A former Goldman Sachs Group Inc. banker went on trial Tuesday for allegedly paying government officials in Ghana a "holy rain" of bribes to secure a lucrative power plant deal for a client. Most Read from Bloomberg Chip Rout Deepens on Circular …

Opaleye group (NASDAQ: GOSS) reports 24.9M-share, 5.10% Gossamer Bio position

Opaleye Management Inc., along with Opaleye, L.P., and James Silverman, has disclosed a 5.10% beneficial ownership stake in Gossamer Bio, Inc. (GOSS), totaling 24,942,565 shares. This includes 24,141,629 shares held directly by Opaleye, L.P. and an additional 800,936 shares in a separately managed account. …

Hedge funds on track for another stellar year on AI boom

By Anirban Sen NEW YORK, July 28 (Reuters) - Global hedge funds are on track for another blockbuster year, as they look to surpass their returns from 2025 after an artificial intelligence boom buoyed first-half ‌performance for money managers across most investment strategies, according …

Update: Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment

Gossamer Bio's stock showed significant pre-bell gains after the company announced its plans to file a New Drug Application (NDA) for its pulmonary arterial hypertension (PAH) treatment, seralutinib. This positive market response follows encouraging trial results for the drug. The company expects to submit …

Zacks.com featured highlights include Alphabet, MasTec and Goldman Sachs

For Immediate Release Chicago, IL – July 28, 2026 – Stocks in this week's article are Alphabet Inc. GOOGL, MasTec, Inc. MTZ and The Goldman Sachs Group, Inc. GS. 3 High-Momentum Stocks to Buy Now Before They Surge For investors seeking to maximize returns, …

Leerink upgrades Gossamer Bio stock rating on FDA feedback

Leerink upgraded Gossamer Bio Inc. (NASDAQ:GOSS) to Outperform from Market Perform, raising its price target to $1.00 following positive FDA feedback on the company's PROSERA trial. The FDA's assessment of the trial's statistical significance as a review issue rather than a filing issue reduced …

Gossamer Bio (GOSS) Projected to Release Quarterly Earnings on Tuesday

Leerink Partners Upgrades Gossamer Bio(GOSS.US) to Buy Rating, Cuts Target Price to $1

Leerink Partners has upgraded its rating for Gossamer Bio (GOSS.US) to "Buy." Despite the upgrade, the target price for the stock has been reduced to $1.

GS|Goldman Sachs Group Inc|Kurs:1039.610|Änderung %:+6.500

Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Gossamer Bio Inc (GOSS), detailing its current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 6.30 and is trading within a range suitable …

Hedge Fund Healthcare Bets Approach Five-Year High

This article first appeared on GuruFocus. Hedge funds increased their bullish exposure to U.S. healthcare stocks to nearly its highest level in five years, according to a Goldman Sachs (NYSE:GS) note. Goldman Sachs, a global investment-banking and asset-management company, said managers added exposure for …

12 Health Care Stocks Moving In Monday's After-Market Session

This article lists 12 healthcare stocks that experienced significant movement in Monday's after-market session, highlighting both gainers and losers. Notable gainers include Gossamer Bio, ProMIS Neurosciences, OPKO Health, OrthoPediatrics, Matinas BioPharma Hldgs, and Olema Pharmaceuticals. Conversely, Radiopharm Theranostics, Redhill Biopharma, HeartSciences, iBio, Cumberland Pharma, …

Gossamer Reacquires Global Seralutinib Rights From Chiesi, Receives $5 Million

Gossamer Bio has reacquired the global development and commercial rights for seralutinib from Chiesi, terminating their 2024 Collaboration and License Agreement. Chiesi will pay Gossamer $5 million for development costs, while Gossamer will pay success-based milestones and royalties to Chiesi. This move returns key …

ALGS|Aligos Therapeutics Inc|Price:4.075|Chg%:-0.005

This article provides a comprehensive stock analysis of Aligos Therapeutics Inc (ALGS), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes strong institutional ownership and a recent "Buy" rating from analysts with a …

Aligos Therapeutics Inc (ALGS) Cash Flow

This article provides an in-depth look at Aligos Therapeutics Inc's (ALGS) cash flow statements, including operating, investing, and financing activities, across quarterly and annual periods. It details various components like net income, capital expenditures, and changes in working capital. The piece also includes an …

T. ROWE PRICE GOLDMAN SACHS PRIVATE MARKETS FUND DEBUTS

New interval fund offers private markets exposure in a single professionally managed portfolio, the latest development from the ongoing strategic collaboration between T. Rowe Price and Goldman Sachs Asset Management BALTIMORE, July 27, 2026 /PRNewswire/ -- T. Rowe Price, a global investment management firm …

Aligos Therapeutics Inc (ALGS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Aligos Therapeutics Inc (ALGS). However, it states that relevant data regarding business segments, regional revenue, and profit contribution for ALGS have not yet been disclosed by the company. The page also displays current stock information …

ALGS|Aligos Therapeutics Inc|Price:4.080|

Aligos Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for liver diseases and viral infections, including chronic hepatitis B (HBV), MASH, and coronaviruses. The company's pipeline features lead candidates like ALG-000184 for HBV, ALG-055009 for MASH, and ALG-097558 for coronavirus infections. …

Gossamer Bio shares jump after FDA update and seralutinib rights return

Gossamer Bio (NASDAQ:GOSS) shares surged 25% following a positive FDA regulatory update for its lead drug candidate, seralutinib, and the regaining of full global rights to the therapy. The company anticipates submitting a New Drug Application (NDA) for seralutinib in pulmonary arterial hypertension (PAH) …

Gossamer Bio stock surges 25% on FDA regulatory update

Gossamer Bio Inc. (NASDAQ:GOSS) shares surged 25% after the company announced a regulatory update from the FDA regarding its drug seralutinib for pulmonary arterial hypertension (PAH) and reacquired worldwide rights to the drug. The company plans to submit a New Drug Application (NDA) for …

3 Great Mutual Fund Picks for Your Retirement

It is never too late to invest in mutual funds for retirement. As such, if you plan to invest in some of the best funds, the Zacks Mutual Fund Rank can provide you with valuable guidance. The best way to shortlist great mutual funds …

Gossamer Bio shares surge after FDA filing update; cash concerns and dilution still loom

Goldman Backs Clarity Act as Democrats Says It 'Falls Short' and Warren Says 'Dead on Arrival'

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Republicans released a revised Crypto Clarity Act draft Wednesday, drawing immediate support from Goldman Sachs CEO David Solomon and rejection from Senate Democrats who called it "dead …

Aligos Therapeutics Inc (ALGS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on Aligos Therapeutics Inc (ALGS) stock, specifically focusing on its dividend history and stock split events. It states that no dividends have been distributed in the past five years and lists multiple upcoming stock split events scheduled for August 15, …

Aligos Therapeutics Inc (ALGS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Aligos Therapeutics Inc (ALGS), listing its major shareholders and their proportions, as well as a breakdown of shareholder types. It also provides institutional shareholding data over several quarters and recent shareholder activity with changes in holdings.

Gossamer Bio, Inc. Revenue Breakdown – SWB:4GB

This article from TradingView provides a high-level overview of Gossamer Bio, Inc.'s financial information on the Stuttgart Stock Exchange (SWB:4GB). It indicates that the primary financial segment information for revenue breakdown, including source and country, is not publicly available on this specific page. The …

Goldman Sachs (GS) Launches Private Markets Platform And Buys AEGIS Hedging Solutions

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Goldman Sachs Group (NYSE:GS) has launched a new private markets platform aimed at wealthy clients, expanding access to alternative investments. Goldman Sachs Alternatives has …

GOSS|Gossamer Bio Inc|Price:0.136|Chg%:-0.006

Gossamer Bio Inc. (GOSS) is a late-stage biopharmaceutical company focusing on seralutinib for pulmonary arterial hypertension. The company exhibits stable fundamentals and high growth potential but is currently considered fairly valued within its industry. Despite weak recent stock market performance, its stock price is …

Form 13D/A Gossamer Bio For: 24 July By Investing.com

This article announces the filing of a Form 13D/A for Gossamer Bio on July 24. The filing is a standard regulatory disclosure related to significant ownership stakes in a company. The article itself is very brief, mainly serving as an announcement for this regulatory …

3 High-Momentum Stocks to Buy Now Before They Surge

For investors seeking to maximize returns, high-momentum stocks merit close attention. To identify stocks with strong upside potential, investors can adopt Richard Driehaus's "buy high and sell higher" strategy, a philosophy he famously championed and that earned him a place on Barron's All-Century Team. …

Goldman Sachs Wants Its Wealthy Clients in on the Next SpaceX Before It Goes Public

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Goldman Sachs is expanding its push into private markets with the launch of a new platform designed to give wealthy clients and family offices greater access to …